I was invested in a company that restored people's eyesight. Phase I didn't have a placebo group because they really never do, but shorts complained in publications as did rival doctors, that you could not know if it was effective without the placebo trial, and so there was a lot of attacking the company, wrongly, for not having a placebo group in Phase I. It was utter nonsense.
They did have a placebo group in their Phase II trial.
However, I always found it quite absurd that a patient could restore tissue that no longer existed, based upon the placebo effect, and see, do eye tests and ride horses, by way of wishful thinking. Unfortunately, that company was so swamped with shorts, including acquirers... that it got bought out cheap. The typical shorts, including AF, said that the complaints of shareholders on the active shorting down into the buyout were just nonsense. I believe such people are a part of a much larger problem in biotech.
Looking forward to their being exposed.